At a very fundamental level, to the extent that they can, they should aim to control as much of the value chain as possible, from raw materials and creation through sales and consumption.
In 2011, the results of the AIM-HIGH study called into question the value of niacin in the treatment of cardiovascular disease in light of their inferiority to statins.